Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavapadon Phase 1b in PD with Motor Fluctuations
NCT02224664Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of tavapadon in Parkinson's disease (PD) (4 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Laboratory Test Abnormalities and 4 more. Started Oct 2014; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02224664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224664.